Physician profile
William John Crain
NPI 1649890286
$7,080.77
in general payments reported to CMS, 2019-2025
26 companies · $1,055 in 2025
The $1,055 reported for 2025 was more than what 81% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,961 · 2023: $3,200 · 2024: $865 · 2025: $1,055.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,120.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,074.90 | 2022-2025 | |
| Alkermes, INC. | $1,014.79 | 2022-2025 | Aristada, Lybalvi, Vivitrol |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $639.50 | 2022-2025 | Caplyta |
| Corium, LLC | $619.39 | 2022-2025 | Azstarys |
| Otsuka America Pharmaceutical, INC. | $428.49 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $394.82 | 2022-2025 | Austedo Xr, Austedo, Austedo Xr |
| Axsome Therapeutics, INC. | $387.39 | 2022-2025 | Auvelity, Sunosi |
| Janssen Pharmaceuticals, INC | $353.95 | 2022-2025 | Spravato |
| Almatica Pharma LLC | $344.87 | 2022-2025 | Loreev Xr, Sertraline Hcl |
| Bausch Health US, LLC | $298.33 | 2022-2024 | Aplenzin, Wellbutrin |
| Neurocrine Biosciences, INC. | $274.87 | 2022-2025 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $244.14 | 2022-2025 | Trintellix |
| Lundbeck LLC | $191.20 | 2022-2023 | Rexulti |
| Vanda Pharmaceuticals INC. | $153.81 | 2022-2023 | Fanapt, Hetlioz |
| Neos Therapeutics, LP | $109.34 | 2022-2023 | Adzenys Xr-Odt |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $95.88 | 2022-2024 | Quviviq |
| Ironshore Pharmaceuticals INC. | $85.59 | 2022-2024 | Jornay Pm |
| Harmony Biosciences LLC | $79.33 | 2023 | Wakix |
| Tris Pharma INC | $66.04 | 2023-2024 | Dyanavel Xr |
| Jazz Pharmaceuticals INC. | $45.90 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $45.37 | 2022 | |
| Indivior INC. | $42.92 | 2022-2024 | Sublocade |
| Supernus Pharmaceuticals, INC. | $30.68 | 2024-2025 | Qelbree |
| Avion Pharmaceuticals | $21.68 | 2023 | Methylphenidate Hydrochloride |
| Vertical Pharmaceuticals, LLC | $21.16 | 2024 | Relexxii |
| Collegium Pharmaceutical, INC. | $16.43 | 2025 | Jornay Pm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Crain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.